Originally published In Press as doi:10.1074/jbc.M908781199 on April 3, 2000
J. Biol. Chem., Vol. 275, Issue 23, 17710-17717, June 9, 2000
Template Requirement and Initiation Site Selection by Hepatitis C
Virus Polymerase on a Minimal Viral RNA Template*
Jong-Won
Oh,
Gwo-Tarng
Sheu, and
Michael M. C.
Lai
From the Howard Hughes Medical Institute and Department of
Molecular Microbiology and Immunology, University of Southern
California School of Medicine,
Los Angeles, California 90033-1054
Received for publication, October 29, 1999, and in revised form, March 6, 2000
 |
ABSTRACT |
RNA-dependent RNA polymerase, NS5B
protein, catalyzes replication of viral genomic RNA, which presumably
initiates from the 3'-end. We have previously shown that NS5B can
utilize the 3'-end 98-nucleotide (nt) X region of the hepatitis C virus
(HCV) genome as a minimal authentic template. In this study, we used
this RNA to characterize the mechanism of RNA synthesis by the
recombinant NS5B. We first showed that NS5B formed a complex with the
3'-end of HCV RNA by binding to both the poly(U-U/C)-rich and X regions of the 3'-untranslated region as well as part of the NS5B-coding sequences. Within the X region, NS5B bound stem II and the
single-stranded region connecting stem-loops I and II. Truncation of 40 nt or more from the 3'-end of the X region abolished its template
activity, whereas X RNA lacking 35 nt or less from the 3'-end retained
template activity, consistent with the NS5B-binding site mapped.
Furthermore, NS5B initiated RNA synthesis from a specific site within
the single-stranded loop I. All of the RNA templates that have a
double-stranded stem at the 3'-end had the same RNA initiation site.
However, the addition of single-stranded nucleotides to the 3'-end of X
RNA or removal of double-stranded structure in stem I generated RNA
products of template size. These results indicate that HCV NS5B
initiates RNA synthesis from a single-stranded region closest to the
3'-end of the X region. These results have implications for the
mechanism of HCV RNA replication and the nature of HCV RNA templates in the infected cells.
 |
INTRODUCTION |
Hepatitis C virus (HCV)1
is the etiological agent of non-A, non-B hepatitis, often causing liver
diseases including chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma (1-4). HCV has a positive-sense,
single-stranded RNA genome of approximately 9700 nucleotides (nt) in
length, which is terminated with a stretch (98 nt) of highly conserved
sequence, termed the X region (5-11). The X region folds into a stable
secondary structure consisting of three stem-loop domains (12, 13).
Upstream of the X region is a stretch of poly(U-U/C)-rich sequences of
variable length and highly variable sequences of about 30-40 nt
(5-11). Infectivity assays showed that the X region and U-U/C-rich
sequences are required for viral infectivity, but the variable
sequences are not (14). As implicated by sequence conservation among
all HCV genotypes, the structure and/or sequence of the X region of HCV
is important for minus-strand RNA synthesis and translational
regulation (15, 16). The replication of HCV RNA is mediated by NS5B,
which is an RNA-dependent RNA polymerase (RdRp)
(16-20).
The initial step of viral RNA replication is recognition of the 3'-end
of RNA template by RdRp, which may occur directly or indirectly with
the help of cellular proteins (21, 22). For example, Q
bacteriophage
replicase recognizes the replicable RNA templates with the help of
cellular factors, including ribosomal protein S1 and translation
elongation factor Tu (23-25), which are also important for template
recognition on certain in vitro selected RNA templates
(26-28). Q
replicase contains two RNA-binding domains; one is the
catalytic site, and the other is for sequence-specific recognition of
template RNA. However, template specificity is conferred by the host
factors. Encephalomyocarditis virus polymerase recognizes the
3'-untranslated region (UTR) of viral RNA only when it contains a
poly(A) tail (29, 30). The influenza virus polymerase PB1 subunit also
specifically binds, via three separate RNA-binding domains, to the 5'-
and 3'-arms of either viral or complementary RNA panhandles (31). In
contrast, poliovirus polymerase appears to bind the viral RNA genome
through a nonspecific cooperative binding mechanism (32). HCV RdRp has
an RNA binding activity and preferentially binds poly(U) and poly(G)
over poly(C) and poly(A) homopolymeric RNA (18). However, no specific
binding of HCV polymerase to the 3'-end of HCV viral RNA has been
reported, although the X region is important for infectivity in
vivo (14) and acts as a minimal RNA template in vitro
(16).
The mechanism of initiation of RNA synthesis by RdRp for most RNA
viruses is poorly understood. Brome mosaic virus RdRp appears to be
able to recognize an internal promoter for subgenomic mRNA synthesis de novo (33, 34). However, it is not clear whether there is a direct interaction between the promoter and viral RdRp holoenzyme, since the purified RdRp complex contained two virus-encoded proteins, the polymerase and helicase, and a subunit of translation elongation factor eIF3 (35). Similarly, bovine diarrhea virus polymerase can also recognize the minimal 21-nt RNA template and synthesize complementary RNA in a primer-independent manner and start
RNA synthesis preferentially from a cytidylate at the most 3'-end of
the template (36).
For HCV polymerase, RNA synthesis has been shown to depend on exogenous
or snap-back RNA primers in vitro (17-20). However, we
recently reported that an HCV NS5B expressed and purified from Escherichia coli is able to initiate RNA synthesis de
novo using the full-length HCV genome or the 3'-end of the HCV
genome in both senses as templates without requirement of a primer
(16). Furthermore, we demonstrated that NS5B can utilize the 98-nt, X
region RNA at the 3'-end of plus-strand HCV genomic RNA as a minimal
template. The upstream sequences including the variable sequence region
and U-U/C-rich tract were found to enhance the efficiency of RNA
synthesis. For the minus-strand template, a minimum of 239 nt at the
3'-end of minus-strand HCV RNA was required for efficient RNA synthesis
in vitro. Thus, our recombinant HCV polymerase by itself
appears to be able to recognize HCV RNA and utilize the X region as a
minimal RNA template. We used this minimal RNA template to further
elucidate the mechanism of HCV RNA synthesis. Our results show that HCV
polymerase can bind to the X region directly, but its binding is
enhanced by an upstream U-U/C-rich tract and part of the NS5B-coding
region. Furthermore, we identified the RNA initiation site and
determined the sequence requirement for initiation of RNA synthesis.
These results shed further light on the mechanism of HCV RNA replication.
 |
EXPERIMENTAL PROCEDURES |
Purification of HCV RdRp NS5B Protein--
Recombinant HCV RdRp
NS5B enzyme was expressed in E. coli BL21 transformed with
plasmid pThNS5B and purified using a Ni2+-nitrilotriacetic
acid (NTA)-agarose column (Qiagen) as described previously (16). The
NS5B-containing fractions were collected and dialyzed against buffer A
(50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 10%
glycerol) and applied to a heparin-Sepharose CL-4B column (Amersham
Pharmacia Biotech) equilibrated in the same buffer. The column was
washed with buffer A and step-eluted with 100 mM to 1 M NaCl. The peak fractions containing pure NS5B were
pooled, and the salt concentration of the pooled fractions was adjusted
to 100 mM NaCl with buffer A without NaCl. The protein was
further purified by passing it through an SP-Sepharose column (Amersham
Pharmacia Biotech) that had been equilibrated with buffer A. The
adsorbed protein was then eluted with a 10-ml linear gradient of NaCl
from 100 mM to 1 M. Fractions (1 ml) were
collected, and small aliquots of the peak fractions were stored at
80 °C after dialyzing against buffer A containing 20% glycerol.
Protein concentrations were determined by Bio-Rad protein assay, and
the purity of protein was estimated by densitometric analysis of a
silver-stained SDS-polyacrylamide gel.
Western Blot Analysis--
NS5B proteins were subjected to a
SDS-10% polyacrylamide gel electrophoresis and electroblotted onto a
nitrocellulose membrane. The membrane was probed with rabbit
anti-His6 antibody (Santa Cruz Biotechnology, Inc.), and
proteins were detected by using goat anti-rabbit IgG conjugated with
peroxidase (American Qualex) and enhanced chemiluminescence (ECL;
Amersham Pharmacia Biotech).
RdRp Activity Assay--
Polymerase activity assays were carried
out as described previously (16). Briefly, 200 ng of RNA template was
incubated with 2 pmol of NS5B enzyme in a 25-µl reaction containing
50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 100 mM potassium glutamate, 5 mM MgCl2,
1 mM dithiothreitol, 20 µg/ml actinomycin D (Sigma), 20 units of RNase inhibitor (Promega), 10% glycerol, 0.5 mM
each ATP, CTP, GTP, and 5 µM UTP with 10 µCi of
[
-32P]UTP (3000 Ci/mmol; NEN Life Science Products)
for 1 h at 25 °C. After reactions, the products were extracted
with acidic phenol emulsion (phenol, chloroform (Ambion), 10% SDS,
0.5 M EDTA (1:1:0.2:0.04)), precipitated with
2.5 volumes of 5 M ammonium acetate/isopropyl alcohol
(1:5), denatured in a denaturing buffer containing 95% formamide with
10 mM EDTA and 0.025% each xylene cyanol and bromphenol blue, and then resolved on an 8 M urea, 6% polyacrylamide
gel (14 × 17 cm). After electrophoresis, gels were stained with
ethidium bromide to localize positions of template RNAs. For better
resolution, products were also analyzed on a 5% denaturing sequencing
gel (38 × 43 cm). The dried gels were exposed to x-ray film, and
the amount of 32P incorporated into the newly synthesized
RNA was quantified using a PhosphorImager (Molecular Dynamics, Inc.,
Sunnyvale, CA).
RNA Preparation--
Wild-type and mutant X region RNAs were
synthesized by in vitro transcription using polymerase chain
reaction-amplified DNA templates fused to bacteriophage T7 RNA
polymerase promoter as described previously (16). The full-length
3'-UTR of HCV containing a long U-U/C-rich tract (81 nt) (named
HCV-3'(+) Full) was amplified by polymerase chain reaction using the
infectious genotype 1b HCV cDNA (7) as a template. The 3'-UTR of
HCV containing a short U-rich sequence (13 nt) (named HCV-3'(X)) was
amplified from an HCV Korean isolate of 1b genotype (15, 16). The FCR RNA, which contains the HCV-3'(+) Full plus the neighboring NS5B-coding region (nt 9300-9364 of the infectious genotype 1b HCV RNA) and the CR
RNA, which contains C-terminal portion of NS5B-coding region only (nt
9300-9364), were amplified in a similar way. The gel-purified polymerase chain reaction-amplified DNA templates were used directly for in vitro transcription using T7 RNA polymerase. After
transcription with T7 RNA polymerase, DNA templates were digested by
RQ1 DNase (Promega) for 15 min at 37 °C. Then in vitro
transcribed RNAs were purified using a Sephadex G-25 spin column,
extracted with acidic phenol/chloroform, and then precipitated with
ethanol. RNA concentrations were estimated by measuring the absorbance at 260 nm.
5'-End Labeling of RNA--
For 5'-end 32P-labeling
of X region and FCR RNAs, in vitro transcripts were
dephosphorylated with shrimp alkaline phosphatase (Roche Molecular
Biochemicals) and phosphorylated with T4 polynucleotide kinase (New
England Biolabs) and [
-32P]ATP (6000 Ci/mmol; NEN Life
Science Products). After heat inactivation of the enzyme, free
nucleotides were removed using a Sephadex G-25 spin column, and the
labeled RNA was purified by electrophoresis on a 6% polyacrylamide gel
containing 8 M urea in 1× TBE buffer (90 mM
Tris base, 90 mM boric acid, 1 mM EDTA, pH
8.2). The labeled RNAs were eluted in 2 ml of a buffer consisting of
0.5 M ammonium acetate, 1 mM EDTA (pH 7.5), and
0.5% SDS. The 5'-end-labeled RNAs were then precipitated with ethanol
and resuspended in double distilled H2O to a final
concentration of 1.2 µM (specific activity: 4.4 × 104 cpm/pmol for X RNA and 3.7 × 104
cpm/pmol for FCR RNA).
Alkaline Hydrolysis of End-Labeled
RNA--
32P-Labeled RNA was incubated with 20 µl of
Na2CO3/NaHCO3 buffer (pH 10) for 20 min at 90 °C. The partially hydrolyzed RNA was mixed with an equal
volume of a denaturing buffer containing 95% formamide with 10 mM EDTA and 0.025% each of xylene cyanol and bromphenol
blue and loaded onto a denaturing polyacrylamide gel.
UV Cross-linking of NS5B to 32P-Labeled HCV
3'-UTR--
32P-Labeled 3'-UTR of HCV RNA genome was
synthesized by in vitro transcription using the HCV-3'(X) or
HCV-3'(+) Full DNA template as described previously (13). UV
cross-linking experiments were carried out in 96-well microtiter plates
in a buffer containing 25 mM HEPES-KOH, pH 7.8, 150 mM NaCl, 5% glycerol, 1 mM EDTA, and 2 mM dithiothreitol. Purified NS5B (1.5 pmol) was
preincubated with 10 µg of yeast tRNA in a 20-µl binding buffer at
30 °C for 10 min. Then 32P-labeled RNA probe (2.5 × 105 cpm) was added to a final concentration of 4 pmol/ml, and the mixture was further incubated for 10 min. UV
cross-linking was conducted as described previously (13). For
competition assays, the indicated amounts of unlabeled RNAs or
homopolymeric RNAs (Amersham Pharmacia Biotech) were preincubated with
NS5B prior to the addition of probe. After UV cross-linking, RNAs were
digested with 2 mg/ml RNase A at 37 °C for 30 min, and the
UV-cross-linked products were subjected to SDS-polyacrylamide gel
electrophoresis. The dried gels were exposed to x-ray films for
autoradiography. The amounts of free and bound RNA were analyzed using
a PhosphorImager (Molecular Dynamics).
Electrophoretic Mobility Shift Assay--
The purified NS5B
diluted to appropriate concentrations in buffer A were mixed with the
radiolabeled RNA in the same buffer and incubated for 15 min at
25 °C. RNA-protein complexes were formed in a 10-µl reaction
mixture in the same buffer as that for the RdRp assay, with the
exception that rNTPs and actinomycin D were omitted. The 5'-end
32P-labeled RNA (50 fmol) was incubated with 2.5 pmol of
NS5B, unless otherwise specified, or increasing amounts of NS5B (0.5, 0.7, 0.9, 1, 2, 3, 4, and 5 pmol) for 15 min on ice and then for an additional 15 min at 25 °C. After reactions, 2 µl of loading
buffer (50% glycerol, 0.01% each xylene cyanol and bromphenol blue)
was added, and the samples were loaded directly onto 1-mm-thick
nondenaturing 4% polyacrylamide (59:1 acrylamide/bisacrylamide) gels.
Gels were prerun at 5 V/cm for 30 min and run at room temperature in
0.5× TBE. For competition assays, increasing amounts of the unlabeled RNAs were preincubated with NS5B for 15 min on ice, and incubation was
continued for 15 min at 25 °C with the labeled RNA. The unlabeled competitor HCV RNAs or homopolymeric RNAs were used in the competition assays.
Footprinting Assay for Probing the NS5B-binding Site on the X
Region--
The 5'-end 32P-labeled X RNA (50 fmol) was
preincubated with 3 pmol of NS5B in buffer A on ice for 15 min and then
at 25 °C for 15 min. After reactions, RNAs were digested with RNase
T1 (Ambion; 0.1 units/reaction) for 15 min at 25 °C in
10 µl of RdRp assay buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 100 mM potassium glutamate, 5 mM MgCl2, 1 mM dithiothreitol, 10%
glycerol). Samples were mixed with an equal volume of the denaturing
buffer, boiled for 2 min, and analyzed by electrophoresis on a 5%
denaturing sequencing gel.
 |
RESULTS |
Expression and Purification of Recombinant NS5B--
We have
previously expressed and purified an enzymatically active, full-length
recombinant HCV NS5B by Ni2+-NTA column chromatography
(16). This preparation contained trace amounts of E. coli
proteins of 75 and 110 kDa, which were detectable by silver staining
but not by Coomassie Blue staining (see Ref. 16; data not shown). To
study RNA binding and enzymatic properties of NS5B, we first performed
further purification of NS5B. The pooled NS5B fractions eluted with
250-350 mM imidazole from Ni2+-NTA column were
loaded on a heparin-Sepharose CL-4B column. The bound NS5B was eluted
as a broad peak by NaCl gradient (Fig.
1A) and was detected by
anti-His6 antibody in Western blotting (Fig. 1B). The main peak fractions (~400-600 mM
NaCl-eluted fraction) were pooled and loaded onto an SP-Sepharose
column after adjusting the NaCl concentration to 100 mM.
The NS5B was eluted with a buffer containing 500-700 mM
NaCl. The eluate with the highest purity, as visualized by silver
staining of a SDS-polyacrylamide gel, was found to be over 98% pure
(Fig. 1C). No contaminating proteins could be detected. The
highly purified NS5B protein (65 kDa) was used for all the experiments
described in this study.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 1.
Expression and purification of HCV NS5B
proteins. The coding region of the NS5B cDNA was cloned behind
six histidine residues and expressed in E. coli BL21 (16).
The recombinant NS5B was purified by Ni2+-NTA
chromatography and heparin-Sepharose chromatography, and finally by an
SP-Sepharose column. A, elution profile of HCV NS5B protein
from a heparin-Sepharose column. The SDS-polyacrylamide gel (10%)
loaded with different fractions eluted from heparin-Sepharose column
with increasing concentrations of NaCl was stained with Coomassie
Brilliant Blue R-250. B, Western blot analysis of the NS5B
eluted from the heparin-Sepharose column. The NS5B was resolved by
SDS-10% polyacrylamide gel electrophoresis and blotted onto a
nitrocellulose membrane, which was subsequently probed using a
polyclonal anti-His6 antibody. C, HCV NS5B
protein (1 µg) from a peak fraction eluted from an SP-Sepharose
column was subjected to SDS-polyacrylamide gel electrophoresis and
visualized by silver staining. The arrowheads indicate the
position of NS5B. The sizes of protein markers are indicated in
kilodaltons.
|
|
Binding of HCV NS5B to the 3'-UTR of HCV Genomic RNA--
To
investigate whether NS5B can directly bind to the 3'-UTR of HCV RNA, we
first performed UV cross-linking studies. We used a full-length 3'-UTR
RNA (HCV-3'(X)), which consists of a stretch of variable sequence, a
short U-rich tract (13 nt), and the X region (15). The purified
recombinant NS5B was incubated with 32P-labeled HCV 3'-UTR,
and the complex was covalently cross-linked by UV irradiation. As shown
in Fig. 2A, a 65-kDa protein
was labeled. To assess the specificity of this cross-linking,
increasing amounts of various unlabeled RNA were used for competition
studies. We found that the unlabeled homologous 3'-UTR RNA competed
very effectively with the labeled RNA for binding (lanes
2-5). We next used homopolymeric RNAs for competition to
assess the nucleotide preference for NS5B binding. Among the
homopolymeric RNAs used (Fig. 2B), poly(U) competed most
efficiently (lanes 5-7), followed by poly(G)
(lanes 11-13). In contrast, poly(C) and poly(A)
were poor competitors (lanes 2-4 and
lanes 8-10, respectively). This order of
competition agrees well with the previous direct filter binding assays
of NS5B using homopolymeric RNAs (17). However, the 98-nt X region alone did not significantly compete for binding; only in the presence of a 500-fold molar excess of unlabeled RNA was some inhibition of NS5B
binding observed (Fig. 2C, lane 5). In
direct UV cross-linking studies using 32P-labeled 98-nt X
RNA, a very weak NS5B band was detected only after a very long exposure
(data not shown). These results indicate that NS5B binds weakly to the
X region. We have also tested the 3'-UTR (HCV-3'(+) Full) from an
infectious HCV genotype 1b RNA (14), which contains a longer (81-nt
U/U-C) pyrimidine-rich tract; comparable binding activity was detected
(data not shown). These results indicate that NS5B binds to the HCV
3'-UTR mainly through interaction with the U-rich sequence. It also
weakly interacts with the X region.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 2.
Binding of HCV NS5B protein to the
full-length HCV 3'-UTR. A, UV cross-linking was
performed using the radiolabeled 3'-UTR RNA probe and NS5B either in
the absence ( ) or presence of the indicated amounts (-fold molar
excess) of unlabeled HCV-3'(X) RNA. A total of 1.5 pmol of the purified
NS5B was cross-linked to the probe in a 20-µl reaction, and the
covalently cross-linked proteins were resolved on a 12% polyacrylamide
gel. Protein size markers are shown in kDa. B, competition
assays using homopolymeric RNAs. Increasing amounts (10, 100, and 500 ng) of various unlabeled homopolymeric RNAs were included in the
cross-linking reactions using the labeled 3'-UTR. C, the
indicated amounts (-fold molar excess shown above the
autoradiogram) of unlabeled X RNA was used as a competitor.
The percentages of UV-cross-linked NS5B as compared with the amount of
NSSB cross-linked in the absence of any competitor are shown at the
bottom of each panel.
|
|
Since UV cross-linking studies showed a weak but still detectable
interaction between NS5B and the X region (data not shown), we took
another approach, electrophoretic mobility shift assay (EMSA), to
characterize the interaction. We first estimated the binding affinity
of NS5B to X RNA. The NS5B proteins at various concentrations were
incubated with a fixed amount of radiolabeled X RNA, and the
RNA-protein complex was resolved on a nondenaturing polyacrylamide gel.
As shown in Fig. 3A, an
RNA-NS5B complex was retarded at the loading wells when increasing
amounts of NS5B were used. The percentage of probe bound to NS5B was
quantified using a PhosphorImager and graphically illustrated in Fig.
3B. The apparent dissociation constant was estimated to be
about 170 nM. The binding affinity of HCV NS5B to this RNA
is lower than those of influenza virus polymerase subunit PB1 to the
viral complementary RNA (70 nM) (31) or Q
replicase to
in vitro selected RNA templates (20-30 nM)
(26-28), but it is slightly higher than that of Q
replicase to
unselected RNA ligand pools (>200 nM). Competition assays
indicated that the NS5B-X RNA interaction can be disrupted efficiently
with a 5-10-fold excess of unlabeled X RNA (Fig.
4A) and also very efficiently
inhibited by poly(U) (Fig. 4B). Other homopolymers were less
effective in competition, with the following order of binding
efficiency: poly(U)
poly(C)
poly(G) > poly(A).
These results were similar to the competition data observed with the full-length 3'-UTR by UV cross-linking, except that poly(C) was a
slightly better competitor than poly(G) for the X RNA probe in EMSA. To
further confirm that the binding of NS5B to X RNA was specific, we used
several X RNA mutants that contain various degrees of deletion of stem
I and/or II for competition assays. These mutants have deletions of 40, 46, and 57 nt from the 3'-end (
40X,
46X, and
57X, respectively),
and none of them can serve as RNA templates (see Ref. 16; see also Fig.
7B, left panel, lanes
9-11). The results showed that all of them competed poorly as compared with the 98-nt X RNA for binding to NS5B (Fig.
4C). These results suggest that NS5B binding to the X region
is necessary for polymerase activity. Nevertheless,
40X RNA competed
slightly better than the
46X and
57X RNAs at 10-fold molar excess,
suggesting that
40X RNA contains part of the NS5B-binding
sequence.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Determination of binding affinity of the
purified NS5B to X RNA. A, EMSA was performed with
radiolabeled 98-nt X RNA and increasing amounts of NS5B. Bound and
unbound RNAs were separated on a native polyacrylamide gel. Free
labeled RNA (F) and RNA-protein complex (C), as
well as a slowly migrating RNA isomer (I) that is evident
even in the absence of a protein (lane 1), are
indicated by arrowheads. B, the percentages of
bound probe are presented graphically to estimate the dissociation
constant.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Specificity of interaction of HCV NS5B with X
RNA. A, EMSA was carried out in the absence ( ) and in
the presence of a 1-100-fold molar excess of unlabeled X RNA.
Increasing amounts of unlabeled X RNA were preincubated with NS5B and
allowed to equilibrate at 25 °C for 15 min prior to the addition of
32P-labeled X RNA. Reactions were allowed to equilibrate
for an additional 15 min and then loaded on a nondenaturing
polyacrylamide gel. The bound (B) and unbound (U)
probes were quantified by PhosphorImager, and the percentages of the
probe bound to NS5B are presented at the bottom of the
panel. B, competition assays were performed with
the increasing amounts of homopolymeric RNAs. Relative amounts of the
RNA-protein complex formed as compared with the amount of complex
formed without a competitor are presented. C, competition
assays with a 5- and 10-fold molar excess of unlabeled X or its
deletion mutants ( 40X, 46X, and 57X, which have a 40-, 46-, and
57-nt deletion from the 3'-end of X RNA template, respectively).
|
|
A previous report suggested that NS5B binds mainly to the 3'-end of the
NS5B-coding region but not to the 3'-UTR of HCV RNA (37). To reconcile
this finding with our results, we examined the NS5B-binding capacity of
an RNA (FCR) that contains the 3'-terminus of the NS5B-coding region
linked to the full-length 3'-UTR of HCV. EMSA analysis showed that this
RNA formed an NS5B-RNA complex (Fig.
5A, lane
2), which could be specifically competed by a 5-fold molar
excess of unlabeled FCR RNA (lanes 3-5). But the
corresponding amounts of the RNA (CR) that consists of only the
NS5B-coding region competed less efficiently (Fig. 5A,
compare lane 3 with lane
6). In contrast, poly(U), but not poly(A), abolished the complex formation as efficiently as the full-length FCR (Fig. 5B). This result suggests that NS5B binds more strongly to
the poly(U) sequence than the NS5B-coding region, in contrast to the published report (37).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 5.
EMSA using the full-length 3'-UTR of HCV RNA
(FCR), which also includes the 3'-end of the NS5B-coding region.
EMSA was carried out using the 32P-labeled FCR RNA in the
absence ( ) and in the presence of a 5-, 10-, and 50-fold molar excess
of various unlabeled competitor RNAs. Increasing amounts of unlabeled
competitor RNA was preincubated with NS5B at 25 °C for 15 min prior
to the addition of 5'-end-labeled FCR RNA. Binding was carried out as
in Fig. 4. The NS5B-RNA complex (C) and free RNA probe
(F) are indicated by arrowheads. FCR,
the full-length 3'-UTR plus the NS5B-coding region. CR,
NS5B-coding region only.
|
|
These data together indicate that NS5B does bind weakly but
specifically to the X RNA, which is the minimal cis-acting
RNA element at the 3'-end of HCV genome for RNA synthesis by NS5B (16).
In addition, NS5B binds to the U-U/C-tract of the 3'-UTR and the 3'-end
of the NS5B-coding region, with the former having a stronger
binding activity.
Footprinting Mapping of NS5B-binding Site on X RNA--
We further
characterized the NS5B-binding site on the X region by footprinting
assays using RNase T1 (which specifically cleaves G-residue
on single-stranded RNA). The 5'-end-labeled X RNA probe was incubated
with the purified NS5B, and the RNA-protein complex was treated with
RNase T1 under limited digestion conditions. As previously
shown (13), most G residues (nt 22, 32, 35, 37, 50, and 73, counting
from the 5'-end of the X region) in the predicted single-stranded
regions of the X RNA were digested with RNase T1 in the
absence of NS5B (Fig. 6A,
lane 2). In addition, three G residues in the
predicted double-stranded regions were weakly digested; these include
the G residue at nt
53, which can potentially base pair with the
terminal U-residue at nt
98, and G at
41 and
42 on stem II
neighboring loop II (Fig. 6A, lane 2).
These residues and nt 50 were protected from RNase T1
digestion in the presence of NS5B (Fig. 6A, lanes
3 and 4, and Fig. 6B, Gs in
open circles). In contrast, Gs on loops I and II
(G at
32,
35,
37, and
73) were not protected. These results
indicate that NS5B binds stem II and the hinge region between stems I
and II. The footprinting result was consistent with the EMSA
competition assays using X deletion mutants, which suggest that NS5B
binds part of stem II and stem I (Fig. 4C). These results
together suggest that NS5B binds stem II, part of stem I (shown in Fig.
5B with the shaded bar), and the hinge
region between the two stems. This footprinting analysis further
confirms the direct binding of NS5B to the X region.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Footprinting analysis of NS5B-X RNA
complex. A, the 5'-end-labeled X RNA was incubated at
25 °C for 15 min in the absence ( ; lane 2)
or presence of increasing amounts of NS5B (lanes
3 and 4) and digested by RNase T1.
Digestion was performed for 15 min at 25 °C with 0.1 unit of RNase
T1 under nondenaturing conditions. The RNA fragments were
then resolved on an 8 M urea, 5% polyacrylamide gel
together with RNA size markers, X/OH (a set of labeled RNA fragments
with a common 5'-end generated by partial alkaline hydrolysis of the
5'-end-labeled X RNA) (lane 1) and X/T1 (a G
ladder prepared by partial digestion of the same labeled X RNA by RNase
T1 (lane 2). The protected sites are
indicated by arrowheads on the right. The
numbers on the left side of the
autoradiogram indicate the major cleavage sites not
protected. B, the locations of the G residues
(open circles) protected by NS5B are presented on
the X RNA secondary structure (13). The NS5B-binding region is
indicated with a shaded bar along stems I and II.
The dashed line represents the uncertain binding
region, which was inferred from the competition analyses (see Fig.
4).
|
|
RNA Synthesis on X RNA Template Is Initiated Selectively from the
Unpaired Nucleotide U78 on the Internal Single-stranded
Region of Loop I--
We previously found that the major HCV
NS5B-synthesized RNA products using X RNA (98 nt) migrated slightly
faster than the template RNA on denaturing polyacrylamide gels (16). To
characterize this product, we first determined exact size of the RNA
product by resolving it on a denaturing polyacrylamide sequencing gel. A series of RNA size markers prepared by partial digestion of the
5'-end-labeled 98-nt X RNA with RNase T1 or alkaline
hydrolysis was run in parallel. The results showed that the size of the
major product from X RNA template is 78 nt long, smaller than the
template RNA (98 nt) (Fig. 7A,
indicated by an arrowhead). To determine whether this RNA
product was initiated internally or initiated from the 3'-end of the
template and terminated prematurely, we tested template activity of
serial 3'-end truncation mutants derived from X RNA. All of those
truncation mutants that retain at least part of the stem I structure
(up to a 15-nt deletion) from the 3'-end could serve as templates for
NS5B and generated the same 78-nt product (Fig. 7B,
left panel, lanes 2-4).
The exact sizes of some of these RNA products (X,
5X,
10X, and
15X) were also analyzed on a denaturing sequencing gel (Fig.
7B, right panel), which showed that
the major RNA products of these templates were exactly 78 nt in length.
These results together suggest that the 78-nt product was not derived
from the 3'-end initiation; instead, it might be the result of an
internal initiation from loop I at nt 78. A 20-nt deletion, which
completely deleted stem I, generated two RNA products of different
sizes (lane 5). Deletion of 25 or 30 nt generated
products nearly equivalent to the respective template sizes
(lanes 6 and 7). Deletion of 35 nt
generated an RNA of exact template size (lane 8).
These results suggest that RNA synthesis by HCV NS5B may be initiated
from the single-stranded sequence closest to the 3'-end of HCV X RNA
template, but the precise point of initiation may vary slightly
depending on the sequence or structure of templates. Most of these
deletion mutant X RNAs were better substrates than X RNA (compare
lane 1 with lanes 2-8); in
particular, the 10- and 35-nt deletion mutants generated 5.3- and
3.4-fold, respectively, more products than the wild-type X RNA. The
40-, 46-, and 57-nt deletion mutants (
40X,
46X, and
57X) were
very poor templates; nevertheless, small amounts of products appeared to be of template size. The loss of template activity of these truncated X mutants corresponded to their inability to bind NS5B efficiently, as shown by competition assay in EMSA (Fig.
4C). Some deletion X mutants also yielded an additional
faint band of high molecular weight products, which might represent RNA
synthesis using folded back RNA templates.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 7.
Determination of the initiation site of RNA
synthesis by HCV NS5B using X RNA template. A, a 5%
polyacrylamide gel electrophoresis autoradiogram showing the major RNA
product by NS5B using the X RNA template. An arrowhead
indicates the position of the major product (nt 78). RNA markers used
are the same as described in the legend to Fig. 6. The positions of G
residues on the X RNA sequences are shown at the left
side of the autoradiogram. B, RNA
products using the truncated X mutants as templates. The numbers of
nucleotides deleted from the 3'-end of X RNA are indicated
before the letter X and presented
above the autoradiogram. White
dots denote the template positions (left
panel). The RNA products from the X, 5X, 10X, and 15X
RNA were also analyzed on a denaturing sequencing gel containing 8 M urea to map the precise initiation site (right
panel). The 78-nt RNA products are indicated by an
arrowhead. C, the initiation site of RNA
synthesis is indicated by an arrow on loop I. The 3'-ends of
truncated X mutants are presented in closed
boxes. SL I-III, stem-loops I-III (13).
|
|
To confirm the site of internal initiation, we made several mutant X
templates containing a single base change at nt 78 (78U
A, C, or G)
and a deletion mutant at nt 77 (del77X). As expected, one-nucleotide
deletion at nt 77 (C) resulted in the synthesis of a product that is 1 nt shorter than the product of the wild-type X template (Fig.
8A, lanes
3 and 4). Substitutions of U78 with
A, C, or G affected the efficiency of RNA synthesis (Fig. 8B), with preference for a pyrimidine ribonucleotide as the
first nucleotide of RNA synthesis. These data together indicate that the HCV polymerase indeed initiated RNA synthesis from the
single-stranded unpaired U residue at nt 78 preferentially.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 8.
Initiation site of RNA synthesis using X RNA
derivatives with a mutation in loop I. A, wild-type X
RNA (X) and a deletion X mutant (d77X) containing
a 1-nt deletion at nt 77 (C) were used for RdRp activity
assays. Products synthesized were resolved on a sequencing gel with the
RNA size makers (lanes 1 and 2) as
described in Fig. 6. B, X mutants with a substitution of
U78 with A (78A), C (78C), or G
(78G) were used for RdRp activity assays. Products were
analyzed as in A. The arrowhead indicates nt
78.
|
|
To assess the potential impact of the upstream HCV RNA sequences on the
initiation site of RNA synthesis by NS5B, we used two full-length
3'-UTR HCV RNAs, which consist of the variable sequence, U-U/C-rich
tract of different lengths, and X region as templates. One of them,
HCV-3'(+) Full (total size 225 nt), is derived from an infectious HCV
1b strain (7) and contains 81 nt of U-U/C sequences. The other,
HCV-3'(X) (total size 152 nt), is derived from a Korean isolate of HCV
(15) and contains 13 U residues. RNA products were analyzed on a
denaturing sequencing gel. When HCV-3'(X) RNA was used as template, two
major RNA products were generated, both of which range between 125 and
135 nt in length (Fig. 9,
lanes 3 and 6, indicated by
open arrowheads) and are smaller than the
template (152 nt) by approximately 20 nt. This result is consistent
with the initiation site within loop I. Similar to the X RNA template,
the HCV-3'(X) RNA did not yield any template-sized products. When
HCV-3'(+) Full RNA, which has a long stretch of U-U/C-rich sequence,
was used as a template, the major products were heterogeneous RNA
ladders in the range of 80-140 nt. These RNAs most likely represent
the polymerase stuttering and abortive synthesis within the U-U/C-rich
sequences (lanes 2 and 5). This
stuttering was not apparent with HCV-3'(X) RNA, which has only 13 U
residues (lane 6). It is significant that the RNA
ladder started almost right after the end of the X sequence. In
addition, the HCV-3'(+) Full RNA also yielded a product of
approximately 200 nt, which is smaller than the template (225 nt)
(indicated by an arrowhead in Fig. 9, lane
2), consistent with its initiation within loop I. The
HCV-3'(+) Full RNA also yielded longer products of approximately 300 nt. The origin of these products is not yet clear. It is possible that
they represent folded back RNA synthesis. For both RNA templates, no
template-sized products were detected. These results suggest that when
the full-length 3'-UTR RNA was used as a template, NS5B also initiated
RNA synthesis from loop I, similar to the X RNA template.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 9.
Analysis of RNA initiation sites using the
full-length 3'-UTR RNAs of HCV containing different lengths of
pyrimidine-rich sequences. The RNA products were resolved on 8 M urea, 5% polyacrylamide sequencing gels. The sizes of
template RNAs and other RNA size markers are indicated. An enlarged
autoradiogram is presented to show the details of the RNA products
(right panel). The primary RNA products from the
predicted internal initiation sites from the different templates are
indicated by different arrowheads. HCV-3'(+) Full is the
full-length 3'-UTR containing 81 nt of U-U/C sequence (from HCV 1b
isolate) (7). HCV-3'(X) is the corresponding RNA containing 13 nt of U
(from a Korean isolate) (13).
|
|
Effects of Single-stranded Nucleotide Extension at the 3'-End of
the X Template on Transcription Initiation--
The results described
above suggested that NS5B can only initiate from single-stranded RNA
regions. To test this idea, we examined whether HCV NS5B could initiate
RNA synthesis from the precise 3'-end of an RNA template if it has
single-stranded sequences at the end of stem I. We constructed a series
of X mutants, which have a 3'-end extension of different lengths (Fig.
10A). Results revealed that
when an extra 4 nt (derived from the XbaI cleavage site
sequence) or 11 nt (from the EcoRI cleavage site) were added to the 3'-end of the X template, the major RNA products were of template size, although the internally initiated products (78 nt) were
still synthesized from the X4 template (Fig. 10B,
lane 3). Similarly, the template with two extra U
nucleotides at the 3'-end, which has been identified by cDNA
cloning of an HCV isolate (11), also generated a template-sized
product, although it is weaker than the internally initiated product
(lane 4). These results suggest that
single-stranded nucleotides added to the 3'-end of X template allowed
HCV polymerase to start from the exact 3'-end and proceed through the
19-base pair-long stem I region. To further support this
interpretation, we mutated
15X RNA by replacing the last 5 nt at the
3'-end (5'-GGCCU-3') with a random sequence (5'-UCGUGA-3') so that the
5-nt base-paired stem region at the 3'-end of the
15X RNA template
was disrupted. This RNA (
15XM, 84 nt) generated a template-size
product (84 nt) (Fig. 10C, lane 2,
indicated by an arrowhead) and a slightly smaller product. These data further established that HCV NS5B initiated RNA synthesis only from the single-stranded RNA sequence closest to the 3'-end.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 10.
Effect of single-stranded nucleotide
extension at the 3'-end of X RNA on the initiation site of RNA
synthesis. A, schematic diagram of RNA templates used
for RdRp activity assays. The nucleotide sequences added to the 3'-end
of X RNA are presented in underlined italic
type. B, an autoradiogram showing the products
resolved on an 8 M urea, 5% polyacrylamide sequencing gel.
White dots denote the positions of the RNA
templates. The 78-nt RNA product is indicated by an
arrowhead. C, an autoradiogram showing the
products from X, 15XM (containing an unpaired 3'-end), and d77X (Fig.
8). The major RNA product of the 15XM RNA (6 nt longer than the 78-nt
product derived from the X RNA) is indicated by an
arrowhead. The templates used for the assays are indicated
above the autoradiograms.
|
|
 |
DISCUSSION |
Initiation of RNA synthesis is a crucial step in the replication
of HCV genome, yet it has been poorly understood because of the lack of
a suitable RdRp assay system that can carry out primer-independent
synthesis. We have recently reported the expression and
characterization of a recombinant HCV RNA polymerase, which is capable
of carrying out de novo RNA synthesis and can utilize the
3'-UTR of the HCV genome as a minimal template (16). These findings
allowed us to study the mechanism of initiation of HCV RNA synthesis
in vitro.
We have demonstrated in this study that HCV NS5B binds weakly but
specifically to the X region at the 3'-end of HCV RNA. The interaction
was detected biochemically by UV cross-linking, footprinting, and EMSA.
By footprinting analysis, we mapped the NS5B-binding site to stem II
and the single-stranded hinge between stems I and II of the X region.
Correspondingly, the RdRp assay showed that this region is necessary
for template activity of the X RNA. The relatively low binding affinity
of NS5B to the X region provides a mechanism for NS5B polymerase to
bind to the promoter to initiate RNA synthesis and yet escape from the
promoter to elongate RNA synthesis. Indeed, it has previously been
shown that the template activity of homopolymeric RNAs for HCV
NS5B-inversely correlated with the binding activities of these RNAs to
NS5B (18). Nevertheless, the NS5B binding activity appears to be
required for an RNA to serve as a template, since
40X,
46X, and
57X mutants, which have lost most of the NS5B-binding activity (Fig.
4C), also lost most of their template activity for NS5B
(Fig. 7B). This conclusion is consistent with the previous
reports that the template activity of RNAs selected based on their
ability to bind Q
replicase correlated with their binding affinity
(26-28). Our studies further showed that NS5B binds the
pyrimidine-rich region and part of the NS5B-coding region at a higher
affinity than the X region. This binding probably contributes to the
selectivity of NS5B for the 3'-end of HCV RNA. It should be noted that
a recent report showed that NS5B interacts mainly with the NS5B-coding
sequences (37) but not the 3'-UTR region, whereas our studies showed
that NS5B binds the U-U/C-rich region more strongly than the
NS5B-coding sequence. This discrepancy may be partially due to the fact
that the NS5B used in the previous study (37) was enzymatically
inactive and thus may not reflect its native conformation. Our results
clearly indicate that HCV NS5B alone is capable of interacting with the
3'-end of HCV genome in the pyrimidine-rich region and the X domain,
which are the cis-acting elements important for the
initiation of RNA synthesis. Also, NS5B alone appears to be sufficient
to initiate RNA synthesis using the X or longer RNA templates. However,
it is possible that other viral proteins or cellular proteins, such as
polypyrimidine tract-binding protein (13), can alter the binding
affinity or polymerase activity of NS5B, particularly on a longer RNA
template, such as the full-length viral genome.
Promoter elements required for initiation of HCV RNA synthesis had been
difficult to study in the past, because the previously reported
recombinant NS5B could copy HCV viral RNA only in a
primer-dependent manner and without template specificity
(17-20). Our recombinant HCV polymerase can carry out
primer-independent de novo RNA synthesis and thus allowed us
to partially map cis-acting elements at the 3'-ends of plus-
and minus-strands of HCV genome (16). The importance of the X region at
the 3'-end of the HCV genome as a promoter for the initiation of RNA
synthesis has been illustrated further in this study by experiments
that showed that the full-length X and its deletion mutants lacking up
to 35 nt from the 3'-end were functional templates, whereas the X
mutants with a deletion of 40 nt or more from the 3'-end were inactive.
Our previous results also showed that deletion of stem III abolished
the template activity of X RNA (16). These results combined suggest
that stem-loops II, III, and part of stem I constitute the minimal
cis-acting element required for NS5B to initiate RNA
synthesis in vitro.
Our studies also revealed an interesting and somewhat surprising
finding that RNA synthesis mediated by NS5B initiated from an internal
3'-most single-stranded nucleotide (U78) of loop I. It is
notable that the 3'-end of the X region is in a perfect double-stranded
form (Stem I). Thus, U78 is the 3'-most single-stranded
nucleotide of the entire X RNA. RNA structure prediction based on
computer modeling showed that X RNA mutants with a deletion of 15 nt or
less from the 3'-end preserved the 3'-end double-stranded structure and
that U78 remains as the 3'-most single-stranded nucleotide
in these RNAs (Fig. 7 and data not shown). Significantly, all of these
deletion mutants initiate RNA synthesis from the same U78.
When additional nucleotides are deleted (20 nt or more) from the
3'-end, stem I is destroyed, and the RNA is predicted to have a
single-stranded 3'-tail attached to stem II; significantly, all of
these templates generated RNA products of template size. These results
suggest that RNA synthesis initiates from the 3'-most single-stranded
nucleotide of the X RNA template. This conclusion is supported by the
finding that the addition of 2 nt or more to the 3'-end of stem I
resulted in an RNA product of template size; the internal initiation
became less prominent (Fig. 10B). Furthermore, for
15XM
RNA, which contains a single-stranded 3'-end because of the disruption
of the 5-nt double-stranded stem in the
15X RNA, RNA synthesis
initiated from the very 3'-end of RNA (Fig. 10C), in
contrast to the -15X RNA, for which RNA synthesis initiated internally.
The efficiency of RNA synthesis varied greatly depending on the nature
of the initiating nucleotide and the length of the single-stranded tail
(Fig. 10, B and C). These findings suggest that
once NS5B binds to stems II and I of the X region, the catalytic center
of the enzyme can only interact with the single-stranded tail of the
RNA to initiate RNA synthesis.
The internal initiation of RNA synthesis by NS5B using the authentic
3'-end RNA was confirmed for both the X region only and the full-length
3'-UTR. The pattern of RNA synthesis from the latter template was more
complex because of the presence of the polypyrimidine tract, which
appears to allow NS5B to stutter and abort prematurely. This mechanism
may explain the extreme heterogeneity in the length of polypyrimidine
tract among various RNAs within the same HCV isolate (10, 11).
Nevertheless, it is clear that the full-length RNA products made from
the full-length 3'-UTR of HCV RNA represented internal initiation
rather than initiation from the very 3'-end.
If this in vitro mechanism of RNA synthesis applies to HCV
RNA synthesis in vivo, how then does the NS5B copy the
full-length viral RNA faithfully without losing genetic information as
a result of internal initiation? First, other viral proteins or
cellular proteins may alter the specificity of initiation of RNA
synthesis. For example, under some conditions, the stable duplex of
stem I may be unwound spontaneously or with the help of HCV helicase, NS3 protein (38, 39), thus allowing NS5B to initiate RNA synthesis from
the 3'-end. Alternatively, the presence of other RNA-binding proteins
(e.g. polypyrimidine tract-binding protein) in the
replication complex may affect the conformation of the polymerase
and/or cis-acting RNA elements and thus alter the initiation
site. A third possibility is that the 3'-end of genomic RNA may be
extended with single-stranded nontemplated nucleotides by cellular
terminal transferases and then used as the template for initiation from
the 3'-end. Indeed, a cDNA clone containing two extra nucleotides
(UU) at the 3'-end has been obtained from an HCV isolate (11). Finally,
another possibility is that HCV polymerase may be able to repair 3'-end genetic information lost during the synthesis of minus-strand RNA,
i.e. during plus-strand RNA synthesis, the 3'-end of the nascent RNA molecules copied from the negative-stranded RNA template may fold back to recover the 3'-end sequences, since stem I has internally complementary sequences. The precise mechanism of the initiation of RNA synthesis in vivo is still an open
question. Nevertheless, our studies have provided new insights into the properties of HCV RNA polymerase and the mechanism of HCV RNA synthesis.
 |
ACKNOWLEDGEMENTS |
We thank Jianwen He and Nam Vo for helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants AI 40038 and AI 47348 (to M. M. C. L).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Investigator of the Howard Hughes Medical Institute. To whom
correspondence should be addressed: Dept. of Molecular Microbiology and
Immunology, University of Southern California School of Medicine, 2011 Zonal Ave., HMR-401, Los Angeles, CA 90033-1054. Tel.: 323-442-1748; Fax: 323-342-9555; E-mail: michlai@hsc.usc.edu.
Published, JBC Papers in Press, April 3, 2000, DOI 10.1074/jbc.M908781199
 |
ABBREVIATIONS |
The abbreviations used are:
HCV, hepatitis C
virus;
nt, nucleotide(s);
RdRp, RNA-dependent RNA
polymerase;
UTR, untranslated region;
EMSA, electrophoretic mobility
shift assay;
NTA, nitrilotriacetic acid.
 |
REFERENCES |
| 1.
|
Choo, Q.-L.,
Kuo, G.,
Weiner, A. J.,
Overby, L. R.,
Bradley, D. W.,
and Houghton, M.
(1989)
Science
244,
359-362
|
| 2.
|
Saito, I.,
Miyamura, T.,
Ohbayashi, A.,
Harada, H.,
Katayama, T.,
Kikuchi, S.,
Watanabe, Y.,
Koi, S.,
Onji, M.,
Ohta, Y.,
Choo, Q.-L.,
Houghton, M.,
and Kuo, G.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6547-6549
|
| 3.
|
Alter, H. J.
(1995)
Blood
85,
1681-1695
|
| 4.
|
Houghton, M.
(1996)
in
Virology
(Fields, B. N.
, Knipe, D. M.
, and Howley, P. M., eds)
, pp. 1035-1058, Lippincott-Raven Publishers, Philadelphia
|
| 5.
|
Kolykhalov, A. A.,
Agapov, E. V.,
Blight, K. J.,
Mihalik, K.,
Feinstone, S. M.,
and Rice, C. M.
(1997)
Science
277,
570-574
|
| 6.
|
Yanagi, M.,
Purcell, R. H.,
Emerson, S. U.,
and Bukh, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8738-8743
|
| 7.
|
Yanagi, M.,
Claire, M. S.,
Shapiro, M.,
Emerson, S. U.,
Purcell, R. H.,
and Bukh, J.
(1998)
Virology
244,
161-172
|
| 8.
|
Tanaka, T.,
Kato, N.,
Cho, M.-J.,
and Shimotohno, K.
(1995)
Biochem. Biophys. Res. Commun.
215,
744-749
|
| 9.
|
Tanaka, T.,
Kato, M.,
Cho, M. -J.,
Sugiyama, K.,
and Shimotohno, K.
(1996)
J. Virol.
70,
3307-3312
|
| 10.
|
Kolykhalov, A. A.,
Feinstone, S. M.,
and Rice, C. M.
(1996)
J. Virol.
70,
3363-3371
|
| 11.
|
Yamada, N.,
Tanihara, K.,
Takada, A.,
Yorihuzi, T.,
Tsutsumi, M.,
Shimomura, H.,
Tsuji, T.,
and Date, T.
(1996)
Virology
223,
255-261
|
| 12.
|
Blight, K. J.,
and Rice, C. M.
(1997)
J. Virol.
71,
7345-7352
|
| 13.
|
Ito, T.,
and Lai, M. M. C.
(1997)
J. Virol.
71,
8698-8706
|
| 14.
|
Yanagi, M.,
Claire, M. S.,
Emerson, S. U.,
Purcell, R. H.,
and Bukh, J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2291-2295
|
| 15.
|
Ito, T.,
Tahara, S. M.,
and Lai, M. M. C.
(1998)
J. Virol.
72,
8789-8796
|
| 16.
|
Oh, J.-W.,
Ito, T.,
and Lai, M. M. C.
(1999)
J. Virol.
73,
7694-7702
|
| 17.
|
Behrens, S. E.,
Tomei, L.,
and De Francesco, R.
(1996)
EMBO J.
15,
12-22
|
| 18.
|
Lohmann, V.,
Korner, F.,
Herian, U.,
and Bartenschlager, R.
(1997)
J. Virol.
71,
8416-8428
|
| 19.
|
Yamashita, T.,
Kaneko, S.,
Shirota, Y.,
Qin, W.,
Nomura, T.,
Kobayashi, K.,
and Murakami, S.
(1998)
J. Biol. Chem.
273,
15479-15486
|
| 20.
|
Ferrari, E.,
Wright-Minogue, J.,
Fang, J. W. S.,
Baroudy, B. M.,
Lau, J. Y. N.,
and Hong, Z.
(1999)
J. Virol.
73,
1649-1654
|
| 21.
|
Lai, M. M. C.
(1998)
Virology
244,
1-12
|
| 22.
|
Strauss, J. H.,
and Strauss, E. G.
(1999)
Science
283,
802-804
|
| 23.
|
Blumenthal, T.,
and Carmichael, G. G.
(1979)
Annu. Rev. Biochem.
48,
525-548
|
| 24.
|
Barrera, I.,
Schuppli, D.,
Sogo, J. M.,
and Weber, H.
(1993)
J. Mol. Biol.
232,
512-521
|
| 25.
|
Schuppli, D.,
Barrera, I.,
and Weber, H.
(1994)
J. Mol. Biol.
243,
811-815
|
| 26.
|
Brown, D.,
and Gold, L.
(1995)
Biochemistry
34,
14765-14774
|
| 27.
|
Brown, D.,
and Gold, L.
(1995)
Biochemistry
34,
14775-14782
|
| 28.
|
Brown, D.,
and Gold, L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11558-11562
|
| 29.
|
Cui, T.,
Sanker, S.,
and Porter, A. G.
(1993)
J. Biol. Chem.
268,
26093-26098
|
| 30.
|
Cui, T.,
and Porter, A. G.
(1995)
Nucl. Acid Res.
23,
377-382
|
| 31.
|
Gonzalez, S.,
and Ortin, J.
(1999)
EMBO J.
18,
3767-3775
|
| 32.
|
Pata, J. D.,
Schultz, S. C.,
and Kirkegaard, K.
(1995)
RNA
1,
466-477
|
| 33.
|
Adkins, S.,
Siegel, R. W.,
Sun, J.-H.,
and Kao, C. C.
(1997)
RNA
3,
634-647
|
| 34.
|
Siegel, R. W.,
Bellon, L.,
Beigelman, L.,
and Kao, C. C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11613-11618
|
| 35.
|
Quadt, R.,
Kao, C. C.,
Browning, K. S.,
Hershberger, R. P.,
and Ahlquist, P.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1498-1502
|
| 36.
|
Kao, C. C.,
Del Vecchio, A. M.,
and Zhong, W.
(1999)
Virology
253,
1-7
|
| 37.
|
Cheng, J.-C.,
Chang, M.-F.,
and Chang, S. C.
(1999)
J. Virol.
73,
7044-7049
|
| 38.
|
Porter, D. J. T.,
Short, S. A.,
Hanlon, M. H.,
Preugschat, F.,
Wilson, J. E.,
Willard, D. H., Jr.,
and Consler, T. G.
(1998)
J. Biol. Chem.
273,
18906-18914
|
| 39.
|
Lin, C.,
and Kim, J. L.
(1999)
J. Virol.
73,
8798-8807
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Nikonov, E. Juronen, and M. Ustav
Functional Characterization of Fingers Subdomain-specific Monoclonal Antibodies Inhibiting the Hepatitis C Virus RNA-dependent RNA Polymerase
J. Biol. Chem.,
August 29, 2008;
283(35):
24089 - 24102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Zhang, D. Harris, and V. N. Pandey
The FUSE Binding Protein Is a Cellular Factor Required for Efficient Replication of Hepatitis C Virus
J. Virol.,
June 15, 2008;
82(12):
5761 - 5773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Binder, D. Quinkert, O. Bochkarova, R. Klein, N. Kezmic, R. Bartenschlager, and V. Lohmann
Identification of Determinants Involved in Initiation of Hepatitis C Virus RNA Synthesis by Using Intergenotypic Replicase Chimeras
J. Virol.,
May 15, 2007;
81(10):
5270 - 5283.
[Abstract]
[Full Text]
[PDF]
|
 |
|